Trial Profile

Adaptive phase 2b clinical study of Stromal Cell Therapy

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allogeneic bone marrow derived mesenchymal stromal cell therapy Orbsen Therapeutics (Primary)
Indications Diabetic nephropathies
Focus Registrational; Therapeutic Use

Most Recent Events

30 Jan 2023 New trial record
26 Jan 2023 According to an Orbsen Therapeutics media release, the company will now seek input from the US Food and Drugs Administration (FDA) and the European Medicines Agency (EMA) for the design of this trial , if successful, could potentially result in the conditional approval of ORBCEL of patients with progressive DKD.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com